Watson's buy of Swiss Actavis approved in EU
BRUSSELS Oct 5 (Reuters) - U.S. drugmaker Watson Pharmaceuticals Inc secured EU regulatory clearance on Friday to buy Swiss peer Actavis Group for at least 4.25 billion euros ($5.53 billion) to reinforce its international reach.
Watson, one of the world's biggest suppliers of generic drugs, said in April that the deal would immediately boost earnings. It forecast synergies of more than $300 million within three years.
The European Commission said in a statement that the deal would not hurt competition.
"The investigation showed that despite significant changes in the competitive situation in some of the markets, a sufficient number of credible and strong competitors will continue to exercise a competitive constraint on the merged entity," the EU watchdog said.
- Exclusive: Secret contract tied NSA and security industry pioneer |
- U.S. aircraft hit by gunfire in South Sudan as conflict worsens
- With Fed out of the way, what's next on Wall Street?
- Analysis: Lost Brazil order raises threat to Boeing fighter jets
- Four men arrested in deadly N.J. shopping mall carjacking